Rol' bisfosfonatov v lechenii raka molochnoy zhelezy
- Authors: Kondrat'eva AP1, Poddubnaya IV1
-
Affiliations:
- РМАПО
- Issue: Vol 6, No 2 (2004)
- Pages: 63-64
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26543
- ID: 26543
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A P Kondrat'eva
РМАПОКафедра онкологии РМАПО
I V Poddubnaya
РМАПОКафедра онкологии РМАПО
References
- Fisher B, Ogborne K et al. Neoplasms of the Breast. Cancer medicine 3d edition. Ed. by J Holland et al. Philadelpia: Lea et Febiger, 1993.
- Моисеенко В.М., Семиглазов В.Ф., Тюляндин С.А. Современное лекарственное лечение местно - распространенного и метастатического рака молочной железы, 1997.
- Fleish H. Bisphosphonates in bone disease. Academic press, 2000.
- Rosen L.S, Gordon D, Antonio B.S et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patient with breast cancer or osteolytic lesions of multiple myeloma: a phase III double - blind, comparative trial. Cancer J 2001; 31, 7 (5): 377-87.
- Senartne S.G, Pirianov G, Mansi J.L et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459-68.
- Boissier S, Ferrers M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion an early event in the formation of bone metastase. Cancer Res 2000; 60: 2949-54.
- Binkley N, Kimmel D, Bruner J et al. Zoledronate prevents the development of absolute osteopenia Following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998; 13: 1775-82.
Supplementary files
